This guide compares the NHS and private routes to Mounjaro: eligibility, cost, and how to decide between them. It draws on NICE, the NHS and the devolved-nation sources. Northern Ireland arrangements are still developing and are not covered in detail here.
The two routes: NHS and private
There are two legitimate ways to get Mounjaro in the UK. The NHS describes it plainly: tirzepatide is available with a prescription, either on the NHS or privately, and should be obtained from a registered pharmacy 4. Both routes supply the genuine injection after a clinical assessment 41.
The difference is not about the safety of the medicine, which is the same either way, but about who funds it and who qualifies4. The NHS route is subsidised but criteria-based and phased; the private route is self-funded but open to people who meet the clinical criteria without qualifying for NHS funding 14.
So choosing between them is really about eligibility and cost, set against the same clinical safeguards 4. The sections below take each in turn, then bring them together into a decision. Our complete Mounjaro guide covers the medicine itself.
NHS eligibility: narrow, phased and by nation
NHS access is much narrower than the licence and differs by nation. In England, NICE recommends tirzepatide for adults with a BMI of at least 35 and a weight-related condition, rolled out in phases over several years, with a lower threshold for several ethnic groups 1. The earliest groups have the highest BMI and most conditions, with eligibility widening from around June 2026 and March 2027 1.
In Scotland, the SMC accepts tirzepatide for restricted use at a BMI of 30 or above with a weight-related condition, under a patient access scheme 2. In Wales, it is currently started only through NHS specialist weight management services while a national approach is developed 3. So the NHS route may be open, closed, or routed through specialist services depending on where you live and your circumstances 123.
The practical consequence is a gap between the licence and NHS funding: you can be eligible by the licence and not yet by the NHS 1. That gap is the main reason people turn to the private route 4.
The phasing in England is worth understanding because it changes over time. Eligibility depends on your BMI and how many weight-related conditions you have, with the earliest groups being those with the highest BMI and most conditions, and broader groups becoming eligible from around June 2026 and March 2027 1. So someone who does not qualify on the NHS today may qualify in an upcoming phase, which is a genuine factor in deciding whether to start privately now 1.
The private route
The private route is self-funded, on prescription from a registered pharmacy, after a clinical assessment 4. It is open to people who meet the clinical criteria for treatment but do not qualify for NHS funding in the current phase, or who prefer not to wait 14.
It supplies the same genuine injection as the NHS route, with the same need for a clinical assessment of suitability 4. The NHS advises buying only from a registered pharmacy, because some websites sell fake weight-loss medicines, so the private route must still go through a regulated, registered source 4.
The trade-off is straightforward: the private route is more accessible but self-funded, while the NHS route is subsidised but criteria-based 14. Neither is less safe; the safeguards are identical 4.
One practical point about the private route is that the cost is ongoing rather than one-off, and it can change as your dose is titrated upward, because higher-strength pens generally cost more 4. So when weighing the private route, it is worth thinking about affordability at the maintenance dose you are likely to reach, not just the starting dose 4. A registered pharmacy can be clear about that, and the clinical assessment and follow-up are part of what the price covers, not optional extras 4.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
Cost: what you pay each way
On the NHS, what you pay depends on the route and nation. In England the standard prescription charge is £9.90 per item, with exemptions for some people, while NHS prescriptions are free in Scotland and Wales 5. Where it is supplied through a specialist service rather than dispensed against a prescription, it may be provided without a charge 5.
The NHS price is also insulated from the medicine's list price, because the NHS buys tirzepatide under a confidential commercial arrangement 15. So the modest per-item charge is not the same as what the medicine costs, and it is not the barrier on the NHS; eligibility is 1.
Privately, you pay the pharmacy's price, which reflects the medicine, the clinical assessment and dispensing, and can change as your dose is titrated upward because higher-strength pens generally cost more 4. This guide does not quote private prices, which vary; what matters for safety is using a registered pharmacy, not finding the lowest figure 4.
| NHS route | Private route | |
|---|---|---|
| Who qualifies | Narrow, phased, by-nation criteria 123 | Anyone meeting the clinical criteria 4 |
| What you pay | £9.90 per item in England; free in Scotland/Wales; sometimes no charge via a service 5 | The pharmacy's self-funded price 4 |
| Supply | Genuine injection, after assessment 4 | Genuine injection, after assessment 4 |
| Safeguard | Registered pharmacy / clinician 4 | Registered pharmacy / clinician 4 |
Which route is right for you
The decision usually comes down to two questions. First, do you qualify on the NHS for your nation, now or in an upcoming phase 1. If you do, the NHS route is the lower-cost option 5. Second, if you do not yet qualify, is private treatment appropriate and affordable for you over time, given the dose may be titrated upward 4.
It is worth asking your GP or pharmacist where you sit relative to the NHS criteria and whether an upcoming phase might open access, because the rollout widens over the next couple of years 1. If NHS access is likely soon, that may shape whether you start privately in the meantime 1.
Whichever route, the clinical question is the same: is Mounjaro appropriate for you, assessed individually, and used alongside diet and activity 64. The route is about funding and access, not about whether the medicine suits you 4.
There is also a continuity point worth raising with your prescriber. If you start privately and later become eligible on the NHS, or vice versa, that is something to plan rather than do abruptly, so that your treatment and any reviews carry over smoothly 41. The medicine and the assessment are the same on both routes, which makes such a transition primarily an administrative and funding matter rather than a clinical restart 4.
Buying safely whichever route you choose
Both routes share one non-negotiable safeguard: a registered pharmacy and a clinical assessment 4. The NHS advises buying only from a registered pharmacy, because some websites sell fake weight-loss medicines 4. That applies just as much to the private route as to the NHS one.
So a safe private route is not a way around the assessment; it includes the same suitability check and supplies the genuine injection 4. A service that skips the assessment, offers an unusually low price, or sells Mounjaro in a form that does not exist is a warning sign whatever the route 4.
If cost is pushing you towards a risky source, the constructive step is to check your NHS eligibility and compare registered pharmacies, not to buy from an unverified seller 14. Genuine treatment through a safe route is worth more than a cheaper counterfeit 4.
The reassuring part of all this is that, once you are with a registered pharmacy on either route, the safety question is settled and you can focus on the treatment itself 4. The decision between NHS and private is then genuinely just about access and cost, weighed against your circumstances, rather than about whether the medicine or the supply is trustworthy 14.
Frequently asked questions
Is Mounjaro cheaper on the NHS than privately?
Where you qualify on the NHS, yes: you pay the standard prescription charge (£9.90 per item in England) or nothing in Scotland and Wales, or sometimes nothing via a specialist service 5. The NHS price is subsidised under a confidential commercial arrangement 1. Privately you pay the pharmacy's self-funded price 4. The main NHS barrier is eligibility, not the per-item cost 1.Can I get Mounjaro on the NHS?
Only if you meet the criteria for your nation, which are narrower than the licence and phased. In England that is a BMI of at least 35 with a weight-related condition, rolled out in stages; Scotland accepts a BMI of 30 or above with a comorbidity; Wales uses specialist services 123. Many people who qualify by licence do not yet qualify on the NHS 1.Is the private route to Mounjaro safe?
Yes, if it goes through a registered pharmacy with a clinical assessment, which supplies the same genuine injection as the NHS route 4. The NHS advises buying only from a registered pharmacy, because some websites sell fake weight-loss medicines 4. A private service that skips the assessment or offers an unusually low price is a warning sign 4.Should I start privately or wait for the NHS?
That depends on whether you qualify on the NHS now or in an upcoming phase, and whether private treatment is appropriate and affordable for you in the meantime 14. It is worth asking your GP or pharmacist where you sit relative to the criteria, since the NHS rollout widens over the next couple of years 1.Is the medicine different on the NHS versus privately?
No. It is the same genuine tirzepatide injection, supplied after a clinical assessment, on both routes 4. The difference is who funds it and who qualifies, not the medicine or its safety 14. Both routes go through a registered pharmacy 4.Can I switch from private to NHS Mounjaro later?
It is possible if you become eligible on the NHS, but it is best planned with your prescriber rather than done abruptly, so your treatment and reviews carry over smoothly 41. Because the medicine and the assessment are the same on both routes, such a move is mainly about funding and access rather than a clinical restart 4. Ask whether you are likely to qualify in an upcoming NHS phase 1.Your next step
The NHS and private routes to Mounjaro differ mainly in who qualifies and what you pay, not in the medicine or its safety. NHS access is narrower than the licence, phased, and varies by nation; the private route is self-funded but open to those who meet the clinical criteria. Both use a registered pharmacy and a clinical assessment.
Ask your GP or pharmacist whether you qualify on the NHS for your nation, now or in an upcoming phase, and weigh that against whether private treatment is appropriate and affordable for you. Whichever route you choose, use only a registered pharmacy, and remember the medicine and the clinical assessment are the same on both, so the choice is genuinely about access and cost rather than about the safety or quality of the treatment itself, which is reassuring whichever way you go, since both deliver the same genuine medicine after the same clinical assessment from a registered pharmacy.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
